Equol is having a moment in Japan’s healthy-ageing category, and brands abroad have started asking for it by name. It is not an isoflavone itself but a metabolite — a compound the body, or specifically gut bacteria, makes from the soy isoflavone daidzein.
That detail matters more than it sounds. Not everyone’s gut bacteria can make equol, which is why Japanese manufacturers now ferment soy germ directly into S-equol rather than leaving it to chance. This guide explains who can and cannot produce equol naturally, what Japanese human trials of S-equol supplementation report, how the ingredient is regulated in Japan, and how to specify a Japan-made equol product.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning an equol product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
Who can make equol, and who cannot
Only a minority of people carry the gut bacteria needed to convert soy isoflavones into equol, and the proportion differs by population.
Whether someone makes equol from dietary daidzein depends mainly on which bacteria live in their gut. People are typically classed as “equol producers” or “non-producers” based on a urine test after a soy or daidzein challenge. A study in the British Journal of Nutrition (2012) notes that only 30–60% of people produce equol, and found that some women changed between producer and non-producer status over time.
This is the reason a fermented, ready-made S-equol ingredient exists at all: it delivers equol to everyone, including the majority who would not otherwise make it from soy alone.
What the research shows
Japanese randomised trials of S-equol supplements, run mostly in women who could not make their own equol, report improvements in bone resorption markers and hot flush frequency, with a smaller and more mixed picture for skin.
| Study | Design | Reported result |
|---|---|---|
| Randomised, placebo-controlled pilot trial, Menopause 2011;18(5):563–574 | 93 equol non-producing postmenopausal Japanese women; placebo, 2 mg, 6 mg or 10 mg natural S-equol per day for 12 months | The 10 mg group showed a significantly larger fall in a urinary bone-resorption marker than placebo (-23.94% vs -2.87%, p=0.020), and whole-body bone mineral density did not decline over the year in that group |
| Randomised, double-blind, placebo-controlled trial, Journal of Women’s Health 2012;21(1):92–100 (DOI 10.1089/jwh.2011.2753) | 160 equol non-producing postmenopausal Japanese women with at least 1 hot flush/day; 10 mg S-equol/day (n=77) or placebo (n=83) for 12 weeks | Hot flush frequency fell further with S-equol than placebo (-58.7% vs -34.5%, p=0.009); neck and shoulder stiffness also improved more with S-equol |
| Randomised, double-blind, placebo-controlled pilot trial, Menopause 2012;19(2):202–210 (DOI 10.1097/gme.0b013e318227427b) | 101 equol non-producing postmenopausal Japanese women; placebo, 10 mg or 30 mg S-equol/day for 12 weeks; crow’s-feet wrinkle area/depth, hydration, water loss and elasticity measured | The 10 mg and 30 mg groups showed a significantly smaller increase in crow’s-feet wrinkle area than placebo; wrinkle depth was visibly suppressed at 30 mg by week 12 |
| Randomised, double-blind, placebo-controlled trial, Menopause 2009;16(1):141–148 | 134 Japanese women aged 40–59, both equol producers (34.3%) and non-producers; placebo, 10 mg equol/day or 10 mg equol three times/day for 12 weeks | Equol supplementation improved mood-related menopausal symptom scores, with the clearest effect in participants who were equol non-producers |
Four points to keep in view:
- Three of the four trials enrolled non-producers only. In those trials, participants were screened out if their own gut bacteria already made equol. The 2009 trial included both groups (34.3% were producers), and its clearest effect was in non-producers, so these results say little about what happens in someone who is already a natural producer.
- Funding is not stated in the trial abstracts. The lead author of the skin trial was based at a pharmaceutical company’s nutraceutical research institute, while the bone trial was led from a national nutrition research institute. Industry involvement does not make results wrong, but it is worth knowing when you read them.
- Sample sizes were small to moderate (93–160 participants) and confined to Japanese postmenopausal women, so the results may not generalise to other populations or ages.
- The skin result was mixed. Wrinkle area improved; not every skin parameter measured (hydration, elasticity, water loss) reached significance in the same trial, and a separate 2025 pilot trial in a mixed population found a significant benefit only for barrier function among participants who tested as S-equol producers, not the group overall.
Checked against the published abstracts on 12 October 2026.
What Japanese products say
Equol is not one of the established function-claim ingredients in Japan, so plan your claims around your own market’s rules rather than a Japanese notification.
Japan’s Foods with Function Claims system lets a business notify the Consumer Affairs Agency of the evidence behind a specific function before sale, and only the wording in that notification may be used on the pack. Equol-containing foods in Japan are generally sold without a notified function claim.
Two lessons for a brand abroad:
- Do not assume a Japanese functional wording exists to borrow. Unlike GABA or hyaluronic acid, equol is not an established function-claim ingredient in Japan.
- Your own market’s rules govern your label. Some markets allow structure/function wording based on your own dossier even without a Japanese precedent; others do not. Confirm with your regulatory adviser before you draft copy.
💬 Need an evidence summary for your regulatory adviser that separates producer-status details from the trial results? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe equol by what was studied, in whom, and under what funding — never as a treatment for menopause.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied in equol non-producing women for bone-related markers and everyday comfort” | Naming menopause, osteoporosis or any condition as something the product treats |
| ”Contains equol (S-equol)” with the amount per serving | ”Clinically proven” without naming the study, its size and its limits |
| Noting who ran and funded each study you cite | Presenting industry-funded pilot results as independently confirmed |
How equol is formulated
Equol used in supplements is produced by fermenting soy germ with specific bacteria, giving a stable powder that is dosed in single-digit to tens of milligrams and suits capsules, tablets or powder sticks.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Hard capsule | Small daily serving, low cost per day, flavourless | Fits combined “beauty” or “healthy ageing” formulas |
| Tablet | Familiar format, easy to dose precisely | Excipient choices affect tablet size at low doses |
| Powder stick or drink mix | Fits routines built around a daily sachet | Taste masking for the soy-derived material |
Decisions that shape the specification:
- Source and confirmed content. Equol for foods is commonly produced by fermenting soy germ (soybean embryonic axis) with specific bacteria that convert daidzein directly to S-equol, rather than relying on a consumer’s own gut bacteria. Ask the supplier for the S-equol content of the material and its production method.
- Amount per serving. Match the amount to a study you intend to cite — for example 10 mg or 30 mg a day in the trials above — rather than an arbitrary figure.
- Soy allergen declaration. Equol is soy-derived. Soy is a major labelled allergen in the United States and the European Union, and appears on Japan’s recommended (non-mandatory) allergen list. Confirm the declaration your market requires.
- Companion ingredients. Equol is often combined with other beauty or bone-support ingredients such as collagen peptide or hyaluronic acid. Each companion needs its own check against Japanese food law.
- Packaging and stability. Equol is a stable, dry material; standard moisture-protective packaging for capsules, tablets or powder sticks is normally sufficient, but confirm shelf-life data from the supplier for your specific format.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Equol itself is used in Japanese foods. As with our lactic acid bacteria guide, the detail that matters most here is specific — a bacterial strain there, producer status here — and general marketing language tends to flatten it. If you plan a combined beauty formula, see our hyaluronic acid guide for a companion ingredient with its own separate evidence base. See the Japan-made supplement OEM page for the full check.
Before you ask for a quotation
A factory can quote accurately once the material, the daily amount, the form and the packaging are fixed.
- Equol source and confirmed S-equol content
- Daily amount and servings per pack
- Dosage form
- Companion ingredients and their amounts
- Soy allergen declaration for your market
- Packaging, and the countries you will sell in
- First order and annual volume
💬 Ready to design a Japan-made equol product? Send us the concept — material, daily amount, form and the countries you will sell in.
Frequently asked questions
1. What is the difference between equol and soy isoflavones?
Soy isoflavones such as daidzein are the starting material. Equol is a metabolite that gut bacteria make from daidzein — and only some people’s gut bacteria can do this, which is why a ready-made equol ingredient exists.
2. What share of people can make their own equol?
It varies by population, with only 30–60% of people producing equol, and a 2012 study found that status can change over time in the same person.
3. What do the Japanese trials of S-equol actually show?
In women who could not make their own equol, small randomised trials reported less bone resorption, fewer hot flushes and some improvement in crow’s-feet wrinkle area with S-equol versus placebo. The trials were small and run in Japanese women, and skin results were mixed across the parameters measured.
4. Is equol a notified Foods with Function Claims ingredient in Japan?
It is not an established function-claim ingredient in Japan. Equol-containing foods there are generally sold without a notified function claim, and your own market’s rules govern your label.
5. How is equol produced for supplements, and is it an allergen concern?
It is commonly made by fermenting soy germ with specific bacteria that convert daidzein directly into S-equol. Because it is soy-derived, it needs a soy allergen declaration in markets such as the United States and the European Union.
Sources: “Natural S-equol decreases bone resorption in postmenopausal, non-equol-producing Japanese women: a pilot randomized, placebo-controlled trial”, Menopause 2011;18(5):563–574 (PMID 21252728); “A Natural S-Equol Supplement Alleviates Hot Flushes and Other Menopausal Symptoms in Equol Nonproducing Postmenopausal Japanese Women”, Journal of Women’s Health 2012;21(1):92–100 (PMID 21992596, DOI 10.1089/jwh.2011.2753); “The effects of natural S-equol supplementation on skin aging in postmenopausal women: a pilot randomized placebo-controlled trial”, Menopause 2012;19(2):202–210 (PMID 21934634, DOI 10.1097/gme.0b013e318227427b); “New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women”, Menopause 2009;16(1):141–148 (PMID 19131846); “Equol production changes over time in premenopausal women”, British Journal of Nutrition 2012;107(8):1201–1206 (PMID 21920062); Consumer Affairs Agency Foods with Function Claims notification search. Checked on 12 October 2026.